Nivolumab (commercialized as Opdivo) is one of the most widely used immunotherapy drugs in modern oncology. As a member of the immune checkpoint inhibitor family, it works by reactivating the immune system—particularly T lymphocytes—to recognize and destroy cancer cells. Since its first approval, Nivolumab has transformed the management of several advanced cancers and has become a standard treatment option in cases where conventional therapies offer limited benefit.
In this article, we explore what Nivolumab is, how it works, its approved clinical uses, and its safety considerations, providing a concise yet comprehensive overview for students, researchers, and healthcare professionals.
I. What Is Nivolumab?
Nivolumab is a fully human IgG4 monoclonal antibody designed to target the programmed death-1 (PD-1) receptor found on activated T cells. Developed by Bristol-Myers Squibb, it belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors, which enhance the body’s ability to mount an effective immune response against tumors.
Approved by regulatory agencies such as the FDA and EMA, Nivolumab has rapidly become a cornerstone of immuno-oncology. Its primary therapeutic goal is to restore anti-tumor immunity that is often suppressed by cancer cells. Unlike chemotherapy, which directly attacks rapidly dividing cells, Nivolumab works by modifying immune signaling pathways—offering a more targeted and durable approach in many cancer types.
Originally introduced for metastatic melanoma, its indications have since expanded to include lung cancer, renal cell carcinoma, lymphoma, and several other malignancies, reflecting its broad clinical utility and consistent efficacy.
II. How Nivolumab Works: Mechanism of Action
Cancer cells often evade destruction by exploiting natural immune regulatory pathways. One of the most important of these is the PD-1/PD-L1 immune checkpoint, a mechanism that normally prevents excessive immune activation and autoimmunity. Tumors overexpress PD-L1 or PD-L2 ligands, which bind to the PD-1 receptor on T cells and send inhibitory signals that silence their activity, allowing the tumor to grow unchecked.
Nivolumab directly targets and binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2. By inhibiting this checkpoint, Nivolumab effectively removes the “brakes” on the immune system. This restores T-cell activation, proliferation, and cytokine production, enabling immune cells to recognize and attack malignant cells more efficiently.
Additionally, Nivolumab helps reshape the tumor microenvironment by promoting infiltration of effector T cells and reducing immunosuppressive signals. This can lead to long-lasting anti-tumor responses, even after treatment ends—a hallmark of immunotherapy.
III. Approved Clinical Uses of Nivolumab
Since its introduction, Nivolumab has gained multiple approvals across a wide range of solid tumors and hematologic malignancies. Its versatility comes from its capacity to restore immune surveillance in cancers that have developed mechanisms to suppress T-cell activity. Below are the major clinical indications where Nivolumab has demonstrated significant therapeutic benefit:
1. Melanoma
Nivolumab was first approved for unresectable or metastatic melanoma, either as monotherapy or in combination with ipilimumab. It is also used as adjuvant therapy after surgical removal of high-risk melanoma to reduce recurrence.
2. Non–Small Cell Lung Cancer (NSCLC)
For patients with previously treated metastatic NSCLC, Nivolumab significantly improves survival compared to standard chemotherapy. It is effective regardless of PD-L1 expression and is commonly used after platinum-based regimens.
3. Renal Cell Carcinoma (RCC)
Nivolumab is approved for advanced RCC, both as a single agent and in combination with ipilimumab for intermediate- and poor-risk patients. This combination has become a leading first-line option.
4. Classical Hodgkin Lymphoma
In relapsed or refractory classical Hodgkin lymphoma, particularly after failure of autologous stem cell transplantation or brentuximab vedotin, Nivolumab provides durable responses.
5. Head and Neck Squamous Cell Carcinoma (HNSCC)
Nivolumab is used for recurrent or metastatic HNSCC in patients whose disease progresses during or after platinum-based therapy.
6. Urothelial Carcinoma
For patients with locally advanced or metastatic bladder cancer that has progressed after platinum chemotherapy, Nivolumab serves as a valuable second-line treatment.
7. Colorectal Cancer (MSI-H or dMMR)
Nivolumab is approved for microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) metastatic colorectal cancer, either alone or in combination with ipilimumab, offering significant benefits in tumors with high immunogenicity.
8. Other Indications
In selected regions, Nivolumab has also been approved for cancers such as gastric cancer, esophageal cancer, and hepatocellular carcinoma, reflecting its expanding therapeutic reach.
Across these indications, Nivolumab is often used when standard treatments have failed or when immunotherapy offers a more durable and tolerable alternative.
IV. Side Effects, Contraindications, and Safety Considerations
While Nivolumab offers significant clinical benefits, it also carries a unique safety profile due to its mechanism of activating the immune system. Unlike chemotherapy-related toxicities, adverse events associated with Nivolumab are often immune-mediated and require early recognition and proper management to avoid severe complications.
1. Common Side Effects
These are generally mild to moderate and may include:
- Fatigue
- Rash and pruritus
- Nausea
- Diarrhea
- Decreased appetite
- Joint or muscle pain
- Low-grade fever
These symptoms often improve with supportive care or temporary treatment interruption.
2. Immune-Related Adverse Events (irAEs)
Nivolumab can trigger inflammation in various organs as a result of heightened immune activation. Key irAEs include:
- Dermatologic: Rash, vitiligo, and dermatitis
- Gastrointestinal: Immune-mediated colitis, which can lead to severe diarrhea or abdominal pain
- Pulmonary: Pneumonitis—a potentially serious lung inflammation
- Hepatic: Hepatitis with elevated liver enzymes
- Endocrine: Thyroid dysfunction (hypothyroidism/hyperthyroidism), adrenal insufficiency, hypophysitis
- Renal: Nephritis causing reduced kidney function
Prompt diagnosis and early intervention, often with corticosteroids or immunosuppressive therapy, are essential for managing these toxicities.
3. Contraindications and Warnings
- Pre-existing autoimmune diseases: Patients with active autoimmune disorders may face higher risk of severe irAEs.
- Organ transplant recipients: Increased risk of graft rejection due to T-cell activation.
- Pregnancy and breastfeeding: Not recommended because of potential risks to the fetus or infant.
4. Safety in Special Populations
- Elderly patients: Generally well tolerated, though monitoring remains essential.
- Patients with poor performance status: Immune-related toxicities may be more challenging to manage.
- Hepatic or renal impairment: Requires careful evaluation and regular laboratory monitoring.
Overall, while Nivolumab is considered highly effective and often better tolerated than traditional chemotherapy, clinicians must remain vigilant for immune-related effects to ensure safe and optimal treatment outcomes.
Conclusion
Nivolumab has reshaped cancer therapy by harnessing the power of the immune system to target and eliminate tumor cells. With proven benefits across multiple cancer types and the ability to generate durable responses, it stands as a key pillar of modern immuno-oncology. Understanding how it works, its clinical applications, and its potential side effects is essential for maximizing its therapeutic impact while ensuring patient safety.
References
- Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. New England Journal of Medicine, 373(17), 1627–1639. https://doi.org/10.1056/NEJMoa1507643
- Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. New England Journal of Medicine, 373(2), 123–135. https://doi.org/10.1056/NEJMoa1504627
- Nivolumab plus ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine, 375(19), 1856–1867. DOI: 10.1056/NEJMoa1414428
- Nivolumab versus everolimus in advanced renal-cell carcinoma. New England Journal of Medicine, 373(19), 1803–1813. https://doi.org/10.1056/NEJMoa1510665
- PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New England Journal of Medicine, 372(4), 311–319. https://doi.org/10.1056/NEJMoa1411087
- Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 375(19), 1856–1867. DOI: 10.1056/NEJMoa1602252
- Nivolumab in metastatic urothelial carcinoma after platinum therapy. Lancet Oncology, 18(3), 312–322. https://doi.org/10.1016/S1470-2045(17)30065-7
- Nivolumab in patients with metastatic DNA mismatch repair–deficient or microsatellite instability–high colorectal cancer. Journal of Clinical Oncology, 36(8), 773–779. https://doi.org/10.1200/JCO.2017.76.9901
- Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443–2454. https://doi.org/10.1056/NEJMoa1200690
